FDA clears Cadence pain drug for review

Cadence Pharmaceuticals' stock shot up on the FDA announcement that the company does not have to conduct any additional studies of Acetavance, an intravenous version of acetaminophen. Cadence expects to submit an NDA in the second quarter of 2009. Release